Castration-resistant Prostate Cancer, Metastatic Disease, Prostate Cancer
Conditions
Brief summary
By incorporating dual-tracer PET/CT (PSMA and FDG) and ctDNA, we aimed to evaluate lesion heterogeneity and genomic change of mCRPC patients receiving novel hormonal therapy. The relationship between treatment response and different molecular characterization, as well as imaging features would also be evaluated.
Interventions
DRUGAbiraterone
Patients would be treated with 1000mg abiraterone qd.
DRUGPrednisone
Patients would be treated with 5mg prednisone bid.
DRUGAndrogen deprivation therapy
Patients would get medical or surgical castration.
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosed as mCRPC according to EAU-ESTRO-SIOG 2016 and PSA \> 10ng/ml; 2. No previous treatment with novel hormonal therapy; 3. ECOG 0-2; 4. Normal organ function, WBC \>= 3000/mm3 or Neutrophil \>= 1500/mm3; 5. Aged 18 to 85 years old when issuing written informed consent; 6. Life expectancy \> 12 months. 7. Consent and able to carry out follow-up visit and cooperate with all other study procedures.
Exclusion criteria
1. Severe disease or other medical conditions suggesting a high risk of death within 1 year, which may interfere with follow-up. Decided by investigator; 2. Diagnosed with any other malignant tumor within 3 years before enrollment; 3. Unable to provide necessary follow-up information; 4. Other conditions that are judged as ineligible by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lesion heterogeneity on dual-tracer PET/CT | 90 days |
| Genomic change | 30 days |
Countries
China
Contacts
Primary ContactBeihe Wang
Outcome results
None listed